Inventaire - your friends and communities are your best library

Genomic diversity of colorectal cancer: Changing landscape and emerging targets

author

Tanios Bekaii-Saab

published in: World Journal of Gastroenterology

date of publication: 2016-07-07

language: English

main subject: colorectal cancer

Cites articles 80

Date

Title

Authors

2015-12-01

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

Jean-Pierre J Issa, Leonard B. Saltz, Garth Powis, Filip Janku
2015-09-21

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer

Adil Daud, Scott Kopetz, Razelle Kurzrock, Eunice L Kwak, David P Ryan
2015-08-01

HER2 activating mutations are targets for colorectal cancer treatment

Francesco Galimi, Francesca Cottino, Simonetta M Leto, Giorgia Migliardi, Adam Searleman, Andrea Bertotti
2015-01-14

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients

Leonard B. Saltz, Eileen M. O'Reilly, Mario E Lacouture
2015-06-25

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Bert Vogelstein, Albert de la Chapelle, Bjarne Bartlett, Kenneth W Kinzler, Ralph H. Hruban, Laura D Wood, James R Eshleman, Todd S Crocenzi, James J Lee, Richard M Goldberg, Drew M Pardoll, Luis Alberto Diaz Jr, Nickolas Papadopoulos, Shibin Zhou, Ross C Donehower, Aleksandra D Eyring, Brandon S Luber, Dan Laheru, Janis M Taube, Toby Cornish, Feriyl Bhaijee
2015-12-01

c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases

Mariana F Gayyed
2015-01-01

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites

Wafik El-Deiry, Bora Lim
2015-10-12

c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence

Wafaey Gomaa
2015-08-08

Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model
2015-05-30

Identification and characterization of RET fusions in advanced colorectal cancer

Samuel J Klempner
2015-07-01

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Giulia Siravegna, Benedetta Mussolin, Giorgio Corti, Giovanni Crisafulli, A Amatu, Simona Lamba, Antonio Avallone, Emanuele Valtorta, Fabiana Tatangelo, Silvio Marco Veronese, Alfredo Budillon, Silvia Marsoni, Alfredo Falcone, Federica Di Nicolantonio, Fotios Loupakis, Salvatore Siena, Andrea Sartore-Bianchi, Alberto Bardelli, Calogero Lauricella, Sebastijan Hobor, Michela Buscarino
2015-03-01

Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer.
2014-09-29

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model

Alicia M Purkey, Aik Choon Tan, Eunice L Kwak, David P Ryan
2014

Cancer statistics, 2014
2014-02-19

Detection of circulating tumor DNA in early- and late-stage human malignancies

Bjarne Bartlett, Alberto Bardelli, Peter Gibbs, Seung-Mo Hong, Yuchen Jiao, Giulia Siravegna, Alessandro Olivi, Andrea Sartore-Bianchi, Salvatore Siena, Silvio Marco Veronese, Victor Velculescu, Luis Alberto Diaz Jr, Bert Vogelstein, Kenneth W Kinzler, John L Cameron, Michael Lim, Jon Weingart, Chetan Bettegowda, Ralph H. Hruban, Laura D Wood, Sueli Mieko Oba Shinjo, Michael Goggins, Daniel A Laheru, George G. Netto, Christopher L Wolfgang, Nickolas Papadopoulos, Nishant Agrawal, Michael A Choti, Rebecca J Leary, Mark Sausen, Michael D Hogarty, Gary L Gallia, Suely Kazue Nagahashi Marie, Brandon S Luber, Isaac Kinde, Robert Giuntoli, Kelly S. Oliner, Henry Brem, Matthias Holdhoff, Hartmut Juhl, Jeanne Tie, Dongmei Xing, Emmanuel S Antonarakis, Evan J Lipson, Calogero Lauricella
2014-10-01

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer

Fotios Loupakis, Chiara Cremolini, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Monica Ronzoni, Giuseppe Tonini, Angela Buonadonna, Alfredo Falcone, Gianluca Tomasello, Alberto Zaniboni, Giacomo Allegrini
2014-08-28

Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions

Ronak H Shah, Vladimir Vacic, Leonard B. Saltz, Jinru Shia
2014-07-31

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Ursula Vehling-Kaiser, Ludwig Fischer von Weikersthal, Tobias Heintges
2014-06-23

Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer

Scott Kopetz
2014-03-31

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color
2014-03-17

Colorectal cancer statistics, 2014.
2014-02-06

Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer

Richard C. Turkington, Kirsty Mclaughlin, Philip D Dunne
2013-06-02

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Victor Velculescu, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Alberto Bardelli, Simona Corso, Emanuele Valtorta, Giulia Siravegna, Giorgia Migliardi, Francesco Galimi, Silvio Marco Veronese, Giorgio Corti, A Amatu, Luis Alberto Diaz Jr, Paolo M. Comoglio, Silvia Giordano, Salvatore Siena, Andrea Bertotti, Mark Sausen, Andrea Cassingena, Livio Trusolino, Marcello Gambacorta, Calogero Lauricella, Sebastijan Hobor, Elisa Scala, Davide Zecchin
2013-09-01

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

Salvatore Siena, Josep Tabernero Caturla, György Bodoky, David Cunningham, Martin Šmakal, Jacek Jassem
2013-06-01

Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology

Moosa Mohammadi
2013-01-26

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Josep Tabernero Caturla, Daniel J. Sargent
2013-10-11

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells

Vincenzo Sforza, Raffaele De Palma, Teresa Troiani, Floriana Morgillo, Anna Capasso, Fortunato Ciardiello, Liberato Berrino
2013-08-13

FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer
2013-07-12

MEK drives cyclin D1 hyperelevation during geroconversion

Mikhail Blagosklonny, Zoya N. Demidenko
2013-05-29

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Helen Marshall, Susan D Richman, Vicky Napp
2012-11

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Igor Puzanov, Adil Daud, Georgina V. Long, Richard F. Kefford, Keith Flaherty, Jeffrey S Weber, Jeffrey A Sosman, Nageatte Ibrahim, Peter F Lebowitz, Omid Hamid, Lynn Schuchter, Jonathan Cebon, Ragini R Kudchadkar, Howard A Burris, Gerald Falchook, Alain P Algazi, Shonda Little, Daniele Ouellet, Kiran D Patel
2012-07-19

Comprehensive molecular characterization of human colon and rectal cancer

Article - wd:Q26739052

Welcome to Inventaire

the library of your friends and communities

learn more